AR093339A1 - Analogos de spliceostatina y metodos para su preparacion - Google Patents

Analogos de spliceostatina y metodos para su preparacion

Info

Publication number
AR093339A1
AR093339A1 ARP130104017A ARP130104017A AR093339A1 AR 093339 A1 AR093339 A1 AR 093339A1 AR P130104017 A ARP130104017 A AR P130104017A AR P130104017 A ARP130104017 A AR P130104017A AR 093339 A1 AR093339 A1 AR 093339A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently selected
nrr
group
hydrogen
Prior art date
Application number
ARP130104017A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR093339A1 publication Critical patent/AR093339A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente se refiere a análogos de spliceostatina citotóxicos y derivados, a sus conjugados farmacológicos de anticuerpos y a métodos para usarlos para tratar enfermedades médicas que incluyen cáncer. Reivindicación 1: Un compuesto de la fórmula (1), en donde: una línea de puntos representa un enlace opcional; cada X¹ está seleccionado, de modo independiente, del grupo que consiste en: -O-, -S- y -NR-; cada X² está seleccionado, de modo independiente, del grupo que consiste en: -O-, -S- y -NR-; R¹ está seleccionado del grupo que consiste en: -R, -OR, -OCOR¹³, -OCONR¹⁴R¹⁵, -OCON(R¹⁴)NR(R¹⁵), =O (doble enlace con oxígeno) y -NR¹⁴R¹⁵; R² y R³ están seleccionados, de modo independiente, del grupo que consiste en: hidrógeno y alquilo C₁₋₆; R⁴ y R⁵ están seleccionados, de modo independiente, del grupo que consiste en: hidrógeno, -OR, -NR¹⁴R¹⁵ y oxo; R⁶ y R⁷ están seleccionados, de modo independiente, del grupo que consiste en: hidrógeno, halógeno, hidroxilo y alquilo C₁₋₆ opcionalmente sustituido con 1 - 3 sustituyentes seleccionados, de modo independiente, de hidroxilo y halógeno, R⁶ y R⁷ forman, junto con el átomo de carbono al que están ligados, un alquilideno C₂₋₅ opcionalmente sustituido con 1 - 3 sustituyentes seleccionados, de modo independiente, de R, R⁶ y R⁷ son juntos oxo o R⁶ y R⁷ forman, junto con el átomo de carbono al que están ligados, un resto de heterocicloalquilo de 3 a 5 miembros que comprende 1 ó 2 heteroátomos seleccionados, de modo independiente, del grupo que consiste en oxígeno, nitrógeno y azufre, en donde dicho resto de heterocicloalquilo puede estar opcionalmente sustituido con uno a tres sustituyentes seleccionados, de modo independiente, de R; R⁸ es hidrógeno, alquilo C₁₋₆ u -OR; R⁹ está seleccionado, de modo independiente, de hidrógeno, -alquilo C₁₋₆, -(C(R)₂)ₘ-C(O)OR, -(C(R)₂)ₘ-C(O)NR¹⁴R¹⁵, -(C(R)₂)ₘ-NR¹⁴R¹⁵, -(C(R)₂)ₘ-N(R)COR¹³, -(C(R)₂)ₘ-C(O)-SR, -(C(R)₂)ₘ-C(O)NR¹⁴N(R)R¹⁵, -(C(R)₂)ₘ-NR-C(O)-NR¹⁴R¹⁵ y -(C(R)₂)ₘ-NR¹⁴N(R)R¹⁵; R¹³ está seleccionado del grupo que consiste en hidrógeno, alquilo C₁₋₆, carbociclilo C₃₋₈, heterociclilo C₃₋₈, alquil C₁₋₆-arilo C₆₋₁₄, alquil C₁₋₆-heteroarilo C₅₋₁₄, en donde R¹³ está opcionalmente sustituido con -NRR o -SO₂NRR; cada R¹⁴ y R¹⁵ está seleccionado, de modo independiente, del grupo que consiste en: hidrógeno, hidroxilo, -NRR, -NRNR₂, -carbociclilo C₃₋₁₀, -alquilen C₁₋₆-carbociclilo C₃₋₁₀, -heterociclilo C₃₋₁₀, -alquilen C₁₋₆-heterociclilo C₃₋₁₀, -(CH₂CH₂O)₁₋₆CH₂CH₂C(O)OR, -(CH₂CH₂O)₁₋₆CH₂CH₂NRR, -alquilo C₁₋₆, arilo C₆₋₁₄, -alquilen C₁₋₆-arilo C₆₋₁₄ y -heteroarilo C₅₋₁₄; o R¹⁴ y R¹⁵, junto con el átomo o los átomos a los que están unidos, forman un anillo heterociclilo C₃₋₁₀, en donde R¹⁴, R¹⁵ o ambos o un anillo formado con R¹⁴ y R¹⁵, están opcionalmente sustituidos con -(C(R)₂)ₘ-R¹⁸ donde cada R¹⁸ está seleccionado, de modo independiente, de (i) -NRR, (ii) -C(NRR)(C(O)OR), (iii) -S-R, (iv) arilo o heteroarilo opcionalmente sustituido con uno o varios de halógeno, -CF₃, -C(R)₂)ₘ-NRR o -(C(R)₂)ₘ-SO₂NRR, (v) -SO₂R, (vi) -S-S-alquil C₁₋₆-C(O)OR, (vii) -SO₂NRR, (viii) -C(O)NRR, (ix) -C(O)OR, (x) -cicloalquilo C₄₋₆ opcionalmente sustituido con -NRR, -SO₂NRR o -NR-C(O)(CH₂)₀₋₆NRR, (xi) -R, (xii) -OR, (xiii) -N(R)NRR, (xiv) -C(O)N(R)NRR, -(C(R)₂)ₘ-O-NRR y -S-S-alquil C₁₋₆-NRR; cada R está seleccionado, de modo independiente, del grupo que consiste en: hidrógeno y -alquilo C₁₋₆; y cada m es, de modo independiente, 0, 1, 2 ó 3; o una de sus sales farmacéuticamente aceptables.
ARP130104017A 2012-11-05 2013-11-04 Analogos de spliceostatina y metodos para su preparacion AR093339A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722769P 2012-11-05 2012-11-05
US201261723645P 2012-11-07 2012-11-07
US201361829409P 2013-05-31 2013-05-31

Publications (1)

Publication Number Publication Date
AR093339A1 true AR093339A1 (es) 2015-06-03

Family

ID=49958508

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104017A AR093339A1 (es) 2012-11-05 2013-11-04 Analogos de spliceostatina y metodos para su preparacion

Country Status (21)

Country Link
US (3) US9169264B2 (es)
EP (1) EP2917195B9 (es)
JP (1) JP6355641B2 (es)
KR (1) KR101762047B1 (es)
CN (1) CN105121421B (es)
AR (1) AR093339A1 (es)
AU (1) AU2013340449B2 (es)
BR (1) BR112015010070B1 (es)
CA (1) CA2890569C (es)
DK (1) DK2917195T5 (es)
ES (1) ES2656298T3 (es)
HK (1) HK1217946A1 (es)
HU (1) HUE036433T2 (es)
IL (1) IL238578B (es)
MX (2) MX361218B (es)
PL (1) PL2917195T3 (es)
PT (1) PT2917195T (es)
RU (1) RU2618523C2 (es)
SI (1) SI2917195T1 (es)
TW (1) TW201431846A (es)
WO (1) WO2014068443A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016011430B1 (pt) * 2013-11-19 2022-09-13 Purdue Research Foundation Compostos, conjugado de anticorpo, composição farmacêutica os compreendendo e seus usos
IL290330B2 (en) 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
TWI777502B (zh) * 2013-12-19 2022-09-11 美商西雅圖遺傳學公司 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
CN106459055B (zh) 2014-01-27 2019-11-01 辉瑞大药厂 双功能细胞毒类药剂
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EA034138B1 (ru) * 2014-09-03 2020-01-09 Иммуноджен, Инк. Цитотоксические бензодиазепиновые производные
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
ES2736106T3 (es) * 2015-03-10 2019-12-26 Bristol Myers Squibb Co Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos
WO2016151432A1 (en) 2015-03-20 2016-09-29 Pfizer Inc. Bifunctional cytotoxic agents containing the cti pharmacophore
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
MA43354A (fr) * 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
EP3165532B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Auristatin derivatives, linker-drugs and ligand-drug conjugates
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
CN114191428A (zh) 2016-03-02 2022-03-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
US11203588B2 (en) 2016-03-10 2021-12-21 The Regents Of The University Of California Anti-cancer and splice modulating compounds and methods
MA45258A (fr) * 2016-06-08 2019-04-17 Univ Rice William M Dérivés de la thailanstatine a, méthodes de traitement et méthodes de synthèse de ceux-ci
WO2018025168A1 (en) 2016-08-03 2018-02-08 Pfizer Inc. Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
EP3515492B1 (en) * 2016-09-23 2023-07-26 Purdue Research Foundation Anti-cancer agents and preparation thereof
EP3522933B1 (en) * 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
BR112019006778A2 (pt) 2016-10-18 2019-10-15 Seattle Genetics Inc Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco
WO2018138591A1 (en) 2017-01-24 2018-08-02 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
CA3056389A1 (en) 2017-03-15 2018-09-20 Eisai R&D Management Co., Ltd. Spliceosome mutations and uses thereof
KR20190141181A (ko) 2017-04-27 2019-12-23 시애틀 지네틱스, 인크. 사차화된 니코틴아미드 아데닌 다이뉴클레오타이드 구제 경로 억제제 콘쥬게이트
MX2020002634A (es) * 2017-09-08 2020-07-13 Marrone Bio Innovations Inc Nuevo compuesto herbicida.
IL273387B2 (en) * 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
EP3720842A4 (en) * 2017-12-06 2021-11-03 Ontario Institute For Cancer Research ACYLHYDRAZONE LINKERS, METHODS, AND USES THEREOF
US11850287B2 (en) 2017-12-22 2023-12-26 Ontario Institute For Cancer Search (Oicr) Heterocyclic acyl hydrazone linkers, methods and uses thereof
JOP20200268A1 (ar) * 2018-06-01 2020-10-26 Eisai R&D Man Co Ltd تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
JP2022512401A (ja) * 2018-12-13 2022-02-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハーボキシジエンスプライシング調節薬抗体－薬物コンジュゲート及びその使用方法
CN109734627A (zh) * 2019-03-04 2019-05-10 浙江华贝药业有限责任公司 一种新的化合物n-2-烷酰基-n-6-芴甲氧羰基-l-赖氨酸
CN109928895A (zh) * 2019-03-04 2019-06-25 浙江华贝药业有限责任公司 一种n-2-烷酰基-n-6-芴甲氧羰基-l-赖氨酸的合成方法
CN109761857A (zh) * 2019-03-04 2019-05-17 浙江华贝药业有限责任公司 N-2-棕榈酰基-n-6-芴甲氧羰基-l-赖氨酸的提纯方法
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2022256467A1 (en) * 2021-06-02 2022-12-08 The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health Compositions and methods comprising deoxy-pentitols

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8902709D0 (en) * 1989-02-07 1989-03-30 Erba Carlo Spa New 4'-epi-4'-amino anthracyclines
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2004010957A2 (en) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CA2479696A1 (en) * 2003-11-11 2005-05-11 Amadeo Parissenti Use of calphostin-c to treat drug-sensitive tumor cells
EP2292248A3 (en) 2005-03-03 2011-06-29 CovX Technologies Ireland Limited Anti-angiogenic compounds
BRPI0617546A2 (pt) * 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
US7825267B2 (en) * 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
WO2009155606A1 (en) * 2008-06-21 2009-12-23 St. Jude Children's Research Hospital Anticancer compounds and methods of making and using same
AR080234A1 (es) 2010-02-25 2012-03-21 Marrone Bio Innovations Inc Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo
EA024118B1 (ru) * 2010-04-15 2016-08-31 Сиэтл Дженетикс, Инк. Конъюгаты пирролбензодиазепина направленного действия
BR112012026213B1 (pt) * 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
JP2012086587A (ja) 2010-10-15 2012-05-10 Hitachi Ltd 鉄道車両
WO2012059882A2 (en) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
SG11201401699WA (en) 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses

Also Published As

Publication number Publication date
AU2013340449B2 (en) 2017-11-30
BR112015010070A2 (es) 2017-08-22
RU2015115954A (ru) 2016-12-20
MX2015005652A (es) 2015-08-20
AU2013340449A1 (en) 2015-05-14
WO2014068443A1 (en) 2014-05-08
PT2917195T (pt) 2018-02-09
US9504669B2 (en) 2016-11-29
JP2015535004A (ja) 2015-12-07
KR101762047B1 (ko) 2017-07-27
CA2890569A1 (en) 2014-05-08
RU2618523C2 (ru) 2017-05-04
TW201431846A (zh) 2014-08-16
EP2917195B9 (en) 2018-05-30
EP2917195A1 (en) 2015-09-16
US9169264B2 (en) 2015-10-27
DK2917195T5 (en) 2018-08-06
CA2890569C (en) 2019-03-05
EP2917195B1 (en) 2017-12-13
IL238578B (en) 2019-05-30
KR20150080618A (ko) 2015-07-09
ES2656298T9 (es) 2018-08-22
BR112015010070B1 (pt) 2022-06-21
US9764040B2 (en) 2017-09-19
SI2917195T1 (en) 2018-04-30
US20170014523A1 (en) 2017-01-19
JP6355641B2 (ja) 2018-07-11
PL2917195T3 (pl) 2018-04-30
IL238578A0 (en) 2015-06-30
CN105121421A (zh) 2015-12-02
HUE036433T2 (hu) 2018-07-30
DK2917195T3 (en) 2018-01-15
US20160022626A1 (en) 2016-01-28
CN105121421B (zh) 2020-10-02
ES2656298T3 (es) 2018-02-26
MX361218B (es) 2018-11-29
HK1217946A1 (zh) 2017-01-27
MX340090B (es) 2016-06-23
US20140134193A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
AR093339A1 (es) Analogos de spliceostatina y metodos para su preparacion
AR123089A2 (es) Compuesto de piridinona
AR092742A1 (es) Piridinonas antifibroticas
AR089285A1 (es) Derivados de betulina
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR099363A1 (es) Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas
AR103252A1 (es) Compuestos de quinazolina
AR117616A1 (es) Compuestos anti-vih
AR093036A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR092347A1 (es) Derivados de azaindol
AR100418A1 (es) Compuestos y composiciones para inducir condrogénesis
AR087102A1 (es) Derivados de bencilamina como inhibidores de la calicreina plasmatica
AR094876A1 (es) Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR122072A1 (es) Moduladores htt para tratar la enfermedad de huntington
AR101077A1 (es) Triterpenoides con actividad inhibidora de la maduración de hiv
AR092288A1 (es) Ligandos del receptor ep1
AR112907A1 (es) Pirazoles inhibidores de monoacilglicerol lipasa (magl)
AR093797A1 (es) Derivados de feniletilpiridina inhibidores de pde-4
AR093035A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR120246A1 (es) Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1
AR111271A1 (es) Inhibidores dobles de magl y faah
AR116392A1 (es) Compuestos de fenoxi-piridil-pirimidina y métodos de uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure